ICOS Agonist mAb Feladilimab Binds to and Activates Primary Human T Cells
human disease
To evaluate the potential functional effects of ICOS costimulation in the setting of human disease, we generated feladilimab, a humanized mAb with an optimized Fc region with reduced potential to bind activating FcγRs. Unlike ICOS-L, which has been shown to bind to the two nearest structurally related proteins CTLA-4 and CD28 (Consistent with our results demonstrating ICOS expression on activated T cells (ICOS has previously been shown to activate AKT in human T cells following engagement of ICOS-L (When used in a plate-bound format to mimic 